Australian adults with bronchiectasis

The first report from the Australian Bronchiectasis Registry

Simone K. Visser, Peter T.P. Bye, Greg J. Fox, Lucy D. Burr, Anne B. Chang, Chien Li Holmes-Liew, Paul King, Peter G. Middleton, Graeme P. Maguire, Daniel Smith, Rachel M. Thomson, Enna Stroil-Salama, Warwick J. Britton, Lucy C. Morgan

    Research output: Contribution to journalArticleResearchpeer-review

    Abstract

    Background/Objective: There are no large, multi-centre studies of Australians with bronchiectasis. The Australian Bronchiectasis Registry (ABR) was established in 2015 to create a longitudinal research platform. We aimed to describe the baseline characteristics of adult ABR participants and assess the impact of disease severity and exacerbation phenotype on quality of life (QoL).

    Methods: The ABR is a centralised database of patients with radiologically confirmed bronchiectasis unrelated to cystic fibrosis. We analysed the baseline data of adult patients (≥18 years).

    Results: From March 2016–August 2018, 799 adults were enrolled from 14 Australian sites. Baseline data were available for 589 adults predominantly from six tertiary centres (420 female, median age 71 years (interquartile range 64–77), 14% with chronic Pseudomonas aeruginosa infection). Most patients had moderate or severe disease based on the Bronchiectasis Severity Index (BSI) (84%) and FACED (59%) composite scores. Using Global Lung function Initiative-2012 reference equations, the majority of patients (48%) had normal spirometry; only 34% had airflow obstruction (FEV1/FVC < LLN). Disease severity scores (BSI and FACED) were negatively correlated with QoL-Bronchiectasis domain scores (rs between −0.09 and −0.58). The frequent exacerbator phenotype (≥3 in the preceding year) was identified in 23%; this group had lower scores in all QoL-B domains (p ≤ 0.001) and more hospitalisations (p < 0.001) than those with <3 exacerbations.

    Conclusions: The largest cohort of Australian adults with bronchiectasis has been described. Using contemporary criteria, most patients with bronchiectasis did not have airflow obstruction. The frequent exacerbation trait connotes poorer QoL and greater health-care utilisation.
    Original languageEnglish
    Pages (from-to)97-103
    Number of pages7
    JournalRespiratory Medicine
    Volume155
    DOIs
    Publication statusPublished - Aug 2019

    Fingerprint

    Bronchiectasis
    Registries
    Quality of Life
    Patient Acceptance of Health Care
    Phenotype
    Pseudomonas Infections
    Spirometry
    Cystic Fibrosis
    Pseudomonas aeruginosa
    Disease Progression
    Hospitalization
    Databases
    Lung

    Cite this

    Visser, S. K., Bye, P. T. P., Fox, G. J., Burr, L. D., Chang, A. B., Holmes-Liew, C. L., ... Morgan, L. C. (2019). Australian adults with bronchiectasis: The first report from the Australian Bronchiectasis Registry. Respiratory Medicine, 155, 97-103. https://doi.org/10.1016/j.rmed.2019.07.016
    Visser, Simone K. ; Bye, Peter T.P. ; Fox, Greg J. ; Burr, Lucy D. ; Chang, Anne B. ; Holmes-Liew, Chien Li ; King, Paul ; Middleton, Peter G. ; Maguire, Graeme P. ; Smith, Daniel ; Thomson, Rachel M. ; Stroil-Salama, Enna ; Britton, Warwick J. ; Morgan, Lucy C. / Australian adults with bronchiectasis : The first report from the Australian Bronchiectasis Registry. In: Respiratory Medicine. 2019 ; Vol. 155. pp. 97-103.
    @article{a5a02ba6eb1547ba80204ac524d71500,
    title = "Australian adults with bronchiectasis: The first report from the Australian Bronchiectasis Registry",
    abstract = "Background/Objective: There are no large, multi-centre studies of Australians with bronchiectasis. The Australian Bronchiectasis Registry (ABR) was established in 2015 to create a longitudinal research platform. We aimed to describe the baseline characteristics of adult ABR participants and assess the impact of disease severity and exacerbation phenotype on quality of life (QoL).Methods: The ABR is a centralised database of patients with radiologically confirmed bronchiectasis unrelated to cystic fibrosis. We analysed the baseline data of adult patients (≥18 years).Results: From March 2016–August 2018, 799 adults were enrolled from 14 Australian sites. Baseline data were available for 589 adults predominantly from six tertiary centres (420 female, median age 71 years (interquartile range 64–77), 14{\%} with chronic Pseudomonas aeruginosa infection). Most patients had moderate or severe disease based on the Bronchiectasis Severity Index (BSI) (84{\%}) and FACED (59{\%}) composite scores. Using Global Lung function Initiative-2012 reference equations, the majority of patients (48{\%}) had normal spirometry; only 34{\%} had airflow obstruction (FEV1/FVC < LLN). Disease severity scores (BSI and FACED) were negatively correlated with QoL-Bronchiectasis domain scores (rs between −0.09 and −0.58). The frequent exacerbator phenotype (≥3 in the preceding year) was identified in 23{\%}; this group had lower scores in all QoL-B domains (p ≤ 0.001) and more hospitalisations (p < 0.001) than those with <3 exacerbations.Conclusions: The largest cohort of Australian adults with bronchiectasis has been described. Using contemporary criteria, most patients with bronchiectasis did not have airflow obstruction. The frequent exacerbation trait connotes poorer QoL and greater health-care utilisation.",
    keywords = "Bronchiectasis, Exacerbations, Phenotype, Quality of life, Registry, Respiratory function tests",
    author = "Visser, {Simone K.} and Bye, {Peter T.P.} and Fox, {Greg J.} and Burr, {Lucy D.} and Chang, {Anne B.} and Holmes-Liew, {Chien Li} and Paul King and Middleton, {Peter G.} and Maguire, {Graeme P.} and Daniel Smith and Thomson, {Rachel M.} and Enna Stroil-Salama and Britton, {Warwick J.} and Morgan, {Lucy C.}",
    year = "2019",
    month = "8",
    doi = "10.1016/j.rmed.2019.07.016",
    language = "English",
    volume = "155",
    pages = "97--103",
    journal = "Respiratory Medicine",
    issn = "0954-6111",
    publisher = "Global Science Books",

    }

    Visser, SK, Bye, PTP, Fox, GJ, Burr, LD, Chang, AB, Holmes-Liew, CL, King, P, Middleton, PG, Maguire, GP, Smith, D, Thomson, RM, Stroil-Salama, E, Britton, WJ & Morgan, LC 2019, 'Australian adults with bronchiectasis: The first report from the Australian Bronchiectasis Registry', Respiratory Medicine, vol. 155, pp. 97-103. https://doi.org/10.1016/j.rmed.2019.07.016

    Australian adults with bronchiectasis : The first report from the Australian Bronchiectasis Registry. / Visser, Simone K.; Bye, Peter T.P.; Fox, Greg J.; Burr, Lucy D.; Chang, Anne B.; Holmes-Liew, Chien Li; King, Paul; Middleton, Peter G.; Maguire, Graeme P.; Smith, Daniel; Thomson, Rachel M.; Stroil-Salama, Enna; Britton, Warwick J.; Morgan, Lucy C.

    In: Respiratory Medicine, Vol. 155, 08.2019, p. 97-103.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - Australian adults with bronchiectasis

    T2 - The first report from the Australian Bronchiectasis Registry

    AU - Visser, Simone K.

    AU - Bye, Peter T.P.

    AU - Fox, Greg J.

    AU - Burr, Lucy D.

    AU - Chang, Anne B.

    AU - Holmes-Liew, Chien Li

    AU - King, Paul

    AU - Middleton, Peter G.

    AU - Maguire, Graeme P.

    AU - Smith, Daniel

    AU - Thomson, Rachel M.

    AU - Stroil-Salama, Enna

    AU - Britton, Warwick J.

    AU - Morgan, Lucy C.

    PY - 2019/8

    Y1 - 2019/8

    N2 - Background/Objective: There are no large, multi-centre studies of Australians with bronchiectasis. The Australian Bronchiectasis Registry (ABR) was established in 2015 to create a longitudinal research platform. We aimed to describe the baseline characteristics of adult ABR participants and assess the impact of disease severity and exacerbation phenotype on quality of life (QoL).Methods: The ABR is a centralised database of patients with radiologically confirmed bronchiectasis unrelated to cystic fibrosis. We analysed the baseline data of adult patients (≥18 years).Results: From March 2016–August 2018, 799 adults were enrolled from 14 Australian sites. Baseline data were available for 589 adults predominantly from six tertiary centres (420 female, median age 71 years (interquartile range 64–77), 14% with chronic Pseudomonas aeruginosa infection). Most patients had moderate or severe disease based on the Bronchiectasis Severity Index (BSI) (84%) and FACED (59%) composite scores. Using Global Lung function Initiative-2012 reference equations, the majority of patients (48%) had normal spirometry; only 34% had airflow obstruction (FEV1/FVC < LLN). Disease severity scores (BSI and FACED) were negatively correlated with QoL-Bronchiectasis domain scores (rs between −0.09 and −0.58). The frequent exacerbator phenotype (≥3 in the preceding year) was identified in 23%; this group had lower scores in all QoL-B domains (p ≤ 0.001) and more hospitalisations (p < 0.001) than those with <3 exacerbations.Conclusions: The largest cohort of Australian adults with bronchiectasis has been described. Using contemporary criteria, most patients with bronchiectasis did not have airflow obstruction. The frequent exacerbation trait connotes poorer QoL and greater health-care utilisation.

    AB - Background/Objective: There are no large, multi-centre studies of Australians with bronchiectasis. The Australian Bronchiectasis Registry (ABR) was established in 2015 to create a longitudinal research platform. We aimed to describe the baseline characteristics of adult ABR participants and assess the impact of disease severity and exacerbation phenotype on quality of life (QoL).Methods: The ABR is a centralised database of patients with radiologically confirmed bronchiectasis unrelated to cystic fibrosis. We analysed the baseline data of adult patients (≥18 years).Results: From March 2016–August 2018, 799 adults were enrolled from 14 Australian sites. Baseline data were available for 589 adults predominantly from six tertiary centres (420 female, median age 71 years (interquartile range 64–77), 14% with chronic Pseudomonas aeruginosa infection). Most patients had moderate or severe disease based on the Bronchiectasis Severity Index (BSI) (84%) and FACED (59%) composite scores. Using Global Lung function Initiative-2012 reference equations, the majority of patients (48%) had normal spirometry; only 34% had airflow obstruction (FEV1/FVC < LLN). Disease severity scores (BSI and FACED) were negatively correlated with QoL-Bronchiectasis domain scores (rs between −0.09 and −0.58). The frequent exacerbator phenotype (≥3 in the preceding year) was identified in 23%; this group had lower scores in all QoL-B domains (p ≤ 0.001) and more hospitalisations (p < 0.001) than those with <3 exacerbations.Conclusions: The largest cohort of Australian adults with bronchiectasis has been described. Using contemporary criteria, most patients with bronchiectasis did not have airflow obstruction. The frequent exacerbation trait connotes poorer QoL and greater health-care utilisation.

    KW - Bronchiectasis

    KW - Exacerbations

    KW - Phenotype

    KW - Quality of life

    KW - Registry

    KW - Respiratory function tests

    UR - http://www.scopus.com/inward/record.url?scp=85069541227&partnerID=8YFLogxK

    U2 - 10.1016/j.rmed.2019.07.016

    DO - 10.1016/j.rmed.2019.07.016

    M3 - Article

    VL - 155

    SP - 97

    EP - 103

    JO - Respiratory Medicine

    JF - Respiratory Medicine

    SN - 0954-6111

    ER -